Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-1431 fMRI study in healthy volunteers
NCT02929264Phase 1Completed
- Sponsor
- Abide Therapeutics
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABX-1431 in pain (3 arms), sponsored by Abide Therapeutics. Primary endpoint: Brain activity in response to noxious stimuli at 5 weeks. Started Dec 2016; status: completed.
02
Drugs
ABX-1431
03
Conditions
pain
Beyond the preview
Go deeper on NCT02929264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929264.